TGF-β, to target or not to target; to prevent thyroid cancer progression?

Karnik, Isha; Sutherland, Rachel; Elson, Joanna L.; Aspinall, Sebastian; Meeson, Annette

doi:10.1016/j.bbcan.2022.188752

Cited by 2 publications

(1 citation statement)

References 74 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Epithelial cell-derived tumor cells acquire the ability to move and invade after EMT and then metastasize to distal through blood and lymphatic circulation. This process is abnormally activated during DTC development (24). DTC cells have been reported to exhibit an active EMT process, characterized by loose epithelial features, polarity, and cohesion, decreased epithelial markers expression and increased mesenchymal markers expression compared with normal thyroid cells (25,26).…”

Section: Discussionmentioning

confidence: 99%

TESC promotes differentiated thyroid cancer development by activating ERK and weakening NIS and radioiodine uptake

et al. 2023

View full text Add to dashboard Cite

Most differentiated thyroid cancer (DTC) patients have a good prognosis after surgery, but radioiodine refractory differentiated thyroid cancer (RAIR-DTC) patients have a signi cantly reduced ve-year survival rate (< 60%) and a signi cantly increased recurrence rate (> 30%). This study aimed to clarify the tescalcin (TESC) role in promoting the malignant PTC progression and providing a potential target for RAIR-DTC treatment. MethodsWe analyzed TESC expression and clinicopathological characteristics using the Cancer Genome Atlas (TCGA) and performed qRT-PCR on tissue samples. TPC-1 and IHH4 proliferation, migration, and invasion were detected after transfection with TESC-RNAi. Using Western blot (WB), several EMT-related indicators were detected. Moreover, iodine uptake of TPC-1 and IHH4 after transfection with TESC-RNAi was detected. Finally, NIS, ERK1/2, and p-ERK1/2 levels were determined by WB. ResultsTESC was signi cantly upregulated in DTC tissues and positively correlated with BRAF V600E mutation based on data analysis from TCGA and our center. Reduced expression of TESC in both IHH-4 (BRAF V600E mutation) and TPC-1 (BRAF V600E wild type) cells signi cantly inhibited cell proliferation, migration, and invasion. It downregulated the EMT pathway markers Vimentin and N-cadherin, and increased E-cadherin. Moreover, TESC knockdown signi cantly inhibited ERK1/2 phosphorylation and decreased NIS expression in DTC cells, with a remarkably increased iodine uptake rate. ConclusionsTESC was highly expressed in DTC tissues and may have promoted metastasis through EMT and induced iodine resistance by downregulating NIS in DTC cells.

show abstract

Section: Discussionmentioning

confidence: 99%

TESC promotes differentiated thyroid cancer development by activating ERK and weakening NIS and radioiodine uptake

et al. 2023

View full text Add to dashboard Cite

show abstract

Mechanism of TESC in the regulation of iodine resistance in differentiated thyroid carcinoma based on ERK-NIS axis

Guo

Cai

Song

et al. 2023

Preprint

View full text Add to dashboard Cite

Purpose Most differentiated thyroid cancer (DTC) patients have a good prognosis after surgery, but radioiodine refractory differentiated thyroid cancer (RAIR-DTC) patients have a significantly reduced five-year survival rate (< 60%) and a significantly increased recurrence rate (> 30%). This study aimed to clarify the tescalcin (TESC) role in promoting the malignant PTC progression and providing a potential target for RAIR-DTC treatment. Methods We analyzed TESC expression and clinicopathological characteristics using the Cancer Genome Atlas (TCGA) and performed qRT-PCR on tissue samples. TPC-1 and IHH4 proliferation, migration, and invasion were detected after transfection with TESC-RNAi. Using Western blot (WB), several EMT-related indicators were detected. Moreover, iodine uptake of TPC-1 and IHH4 after transfection with TESC-RNAi was detected. Finally, NIS, ERK1/2, and p-ERK1/2 levels were determined by WB. Results TESC was significantly upregulated in DTC tissues and positively correlated with BRAF V600E mutation based on data analysis from TCGA and our center. Reduced expression of TESC in both IHH-4 (BRAF V600E mutation) and TPC-1 (BRAF V600E wild type) cells significantly inhibited cell proliferation, migration, and invasion. It downregulated the EMT pathway markers Vimentin and N-cadherin, and increased E- cadherin. Moreover, TESC knockdown significantly inhibited ERK1/2 phosphorylation and decreased NIS expression in DTC cells, with a remarkably increased iodine uptake rate. Conclusions TESC was highly expressed in DTC tissues and may have promoted metastasis through EMT and induced iodine resistance by downregulating NIS in DTC cells.

show abstract

TGF-β, to target or not to target; to prevent thyroid cancer progression?

Cited by 2 publications

References 74 publications

TESC promotes differentiated thyroid cancer development by activating ERK and weakening NIS and radioiodine uptake

TESC promotes differentiated thyroid cancer development by activating ERK and weakening NIS and radioiodine uptake

Mechanism of TESC in the regulation of iodine resistance in differentiated thyroid carcinoma based on ERK-NIS axis

Contact Info

Product

Resources

About